Results 51 to 60 of about 4,653 (155)
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
BMC Geriatrics, 2012 Background The incidence of gout rises with increasing age. Management of elderly (≥65 years) gout patients can be challenging due to high rates of comorbidities, such as renal impairment and cardiovascular disease, and concomitant medication use ...
Jackson Robert L +2 more
doaj +1 more source
eFood, Volume 7, Issue 4, August 2026.Traditional fermented Kimchi “paocai”, commonly consumed in Northeast China, was screened for probiotic resources capable of degrading uric acid in vitro and alleviating hyperuricemia in a mouse model. Abstract Current pharmacological therapies for hyperuricemia (HUA), though effective, pose safety concerns, including allopurinol‐induced severe dermal ...
Aman Khan +8 more
wiley +1 more source
Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.Isobavachin alleviates HUA‐induced oxidative stress, inflammation, and fibrosis in the kidney and heart, potentially through its dual role in promoting UA excretion and inhibiting NF‐κB signaling and NLRP3 inflammasome activation. ABSTRACT Hyperuricaemia (HUA) is a recognized risk factor for cardiovascular and renal diseases.
Yongmei Li +9 more
wiley +1 more source
Nucleotide Metabolism in Health and Disease
MedComm, Volume 7, Issue 8, August 2026.Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao +7 more
wiley +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.We developed a GalNAc‐conjugated siRNA targeting hepatic XDH, which effectively reduces uric acid production by silencing XDH expression, offering a promising therapeutic approach for hyperuricemia. ABSTRACT Hyperuricemia (HUA) is primarily driven by hepatic overproduction of urate, mediated by xanthine dehydrogenase (XDH).
Tingke Tang +12 more
wiley +1 more source
Arthritis Research & Therapy, 2019 Background This study investigates the association between exposure to urate-lowering drugs (ULDs) and progression and recovery from chronic kidney disease (CKD). Methods We identified 5860 incident gout patients at Chang Gung Memorial Hospital from 2012
Ting-Ting Chung +9 more
doaj +1 more source
Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.ABSTRACT The 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitor rosuvastatin is a substrate of breast cancer resistance protein (BCRP). BCRP inhibition increases rosuvastatin plasma concentrations and may result in concentration‐dependent muscle toxicity, at worst rhabdomyolysis.
Ronja Levomäki +3 more
wiley +1 more source
Acta Crystallographica Section E, 2011 In the title compound {systematic name: [2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid (febuxostat) methanol monosolvate}, C16H16N2O3S·CH4O, the benzene and thiazole rings in the febuxostat molecule are twisted at 5.3 ...
Qi-Ying Jiang +4 more
doaj +1 more source
Chemical Biology &Drug Design, Volume 108, Issue 2, August 2026.The graphical abstract illustrates the action mechanisms through which PPE alleviates HUA by inhibiting XOD activity, and by suppressing the PI3K‐AKT signaling pathway to downregulate the expression of the urate reabsorption transporters URAT1 and GLUT9, thereby promoting renal UA excretion and attenuating renal injury.
Zeyu Yin +6 more
wiley +1 more source